Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Phase 1/2 Completed 10 enrolled Inozyme Pharma IQVIA Biotech · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ABCC6 Deficiency.

Timeline

Start: 2022-04-11
Primary completion: 2024-07-09
Completion: 2024-07-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INZ-701	Protein / enzyme biologic	0.2 mg/kg	—
Subject	INZ-701	Protein / enzyme biologic	0.6 mg/kg	—
Subject	INZ-701	Protein / enzyme biologic	1.8 mg/kg	—

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

Summary

Timeline

Drugs

Indications